Sequenom to Debut T21 LDT by End of 2011; Sheds Light on FDA's Vexing Letter

The firm also said its second CLIA lab, rising in San Diego, will be operational in the fourth quarter and will be the one to run the T21 test. Its first CLIA lab, the Center for Molecular Medicine, is based in Grand Rapids, Mich.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Um, why don't they just call

Um, why don't they just call James L. Woods or Cecily Jones and ask what test the FDA meant? The letter said "please feel free to call" if they have any questions...

Brian, that would take all

Brian, that would take all the fun out of it! Actually, I did, and they said they wouldn't comment beyond what's in the letter. It was in the original post [http://www.genomeweb.com/blog/fda-deals-sequenom-blow-says-sequredx-appears-be-ivd].